Viking therapy today
Viking therapy
As of 2:10 pm on the east
- 52-week range
- $ 18.92
▼
$ 81.86
- Value is valuable
- $ 89.75
Viking Therapeutics Inc. NASDAQ: VKTX He took investors on a wild trip since the beginning of 2024. At some point, VKTX shares increased by 375% From the point of view of the closure of January 2, 2024. But this was a stable movement below. As of the closure of the market on April 15, 2025, shares are within 10% of this January 2024.
Only this week was wild. The Vikings shares increased by about 12% from the news that he was preparing to start a phase 3 examination for his drug candidate to reduce weight GLP-1, VK2735. Nevertheless, the shares are struggled to keep these profits, since investors received a reminder of the practical costs of these drugs that could restrain adoption.
GLP-1 drugs were one of the most effective shares in 2024. But the popularity of drugs contains the cost. And to find out how to manage this value, should report your decision to buy VKTX shares.
VK2735 has a change in the game
If you are a beginner in this niche, GLP-1 preparations are subcutaneous. This is an exact medical way to say that patients should have a shot under the skin. The same applies to VK2735, but it is also where the company can have a changing game.
In particular, the company also tests the oral version of VK2735. This would eliminate one obstacle that patients have with injection drugs (i.e. fear for needles). In addition, some testing suggests that the GLP-1 oral preparations may have a lower speed of side effects. A compromise, however, it may be that it takes more time to deliver The results of weight lossField
Investors sell news from Washington
GLP-1 preparations bring huge advantages to patients. Nevertheless, these advantages are at huge costs. At the time of writing this article, these drugs are not covered with Medicare or Medicaid when used for weight loss.
Shares of GLP-1 companies such as Novo Nordisk A/S NYSE: NVO and Eli Lilly & Co. NYSE: Lly The shot in November 2024, when the Biden administration proposed a new rule that would cover the GLP-1 Medicare and Medicaid drugs for low income and elderly patients with a body weight (BMI) index of more than 7 million.
Nevertheless, on April 11, the centers of Medicare and Medicaid Services (CMS) announced that the Biden rule would not complete. The organization did not provide additional comments. The Secretary of Health and Social Services Robert Kennedy, admitting that GLP-1 drugs take place in the treatment of obesity, expressed preference that changes in lifestyle were obvious before transferring patients to obesity drugs.
Regardless of the personal preferences of the secretary of Kennedy, the task will be to find out the regulatory framework for GLP-1 drugs, since this is due to Medicare and Medicaid. Current estimates say that the addition of such a coating will significantly increase the cost of healthcare. In fact, Kennedy said that one assessment showed that the average employer would have to double his current amount for healthcare expenses.
VKTX shares will require condemnation
Viking Therapeutics Promotions Today today
$ 89.75
290.39% growthModerate purchase
Based on 13 analysts ratings
| The current price | $ 22.99 |
|---|---|
| High forecast | $ 138.00 |
| Average forecast | $ 89.75 |
| Low forecast | $ 30.00 |
Details of the forecast of viking funds
The conclusion for investors lies in the fact that viking therapy can become a multi -icing action in time. As of April 15, 2025, analyst the Vikings analyst forecasts on Marketbeat have Consensus target price in the amount of $ 89.75, which will be more than 288%.
However, as investors with other medical actions have seen, you will have to keep shares for several years before VK2735 receives approval. And this suggests that he receives approval. And by this moment, there will probably be competition from other biopharmaceutical companies. In addition, the regulatory environment in Washington can dilute the potential potential for investors.
Promotions are popular among traders, especially short sellers. A short share in VKTX shares exceeds 20%Which says that the action may not yet find the bottom.
After all this, if you are still interested in getting aboard, you will want to wait until the company is a report Profit April 23Trade, probably, will probably be unstable between this from time to time, and even if the report is strong, you will still have time to start the position.
Before considering the Viking therapy, you will want to hear it.
Marketbeat monitors the highest and most effective analysts with the most effective Wall Street analysts and promotions that they recommend to their customers daily. Marketbeat has identified five shares that leading analysts quietly whisper to their clients to buy now before the wider market wins … and there was no wiking therapy on the list.
While Viking Therapeutics currently has a moderate purchase rating among analysts, analysts with the highest rating believe that these five promotions are better buying.
View five shares here
Need to place your plan 401k or Roth Ira? Use these investigation strategies that have time -tested time to increase the monthly pension income that generates your shares portfolio.
Get this free report